Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2017

Monday, March 20, 2017 3:21
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Ethocle Reports has published its latest Market Research Report on Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2017. Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Browse market data tables and figures.

 

                                                                                                                  Published On: 15-Mar-2017 | Pages: 167

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder – Pipeline Review, H1 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Capture.PNG    d.PNG    dd.PNG

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Table of Contents

Introduction

Global Markets Direct Report Coverage

Attention Deficit Hyperactivity Disorder (ADHD) – Overview

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Development

Pipeline Overview

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment

Assessment by Target

Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development

Aevi Genomic Medicine Inc

Alcobra Ltd

Amarantus Bioscience Holdings Inc

 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.